Medication effect on lymphocyte morphology in schizophrenia.

Area of Science:

• Neuroimmunology
• Hematology
• Psychiatry

Background:

• Contradictory findings exist regarding atypical lymphocytes in schizophrenia, with debates on whether they are a genetic marker or drug effect.
• Previous research lacks consensus on the role and prevalence of atypical lymphocytes in neurological and psychiatric disorders.

Purpose of the Study:

• To investigate the occurrence of atypical lymphocytes in schizophrenia patients, comparing those on and off antipsychotic medication.
• To determine if atypical lymphocytes are elevated in Huntington's disease patients compared to normal controls.
• To clarify the association between atypical lymphocytes and schizophrenia, independent of antipsychotic treatment.

Main Methods:

• Blind measurement of atypical lymphocytes in peripheral blood.
• Study groups included 14 schizophrenia patients (on/off medication), 10 Huntington's disease patients (on medication), and 10 healthy controls.
• Statistical analysis to compare atypical lymphocyte percentages between groups.

Main Results:

• Schizophrenia patients showed significantly higher atypical lymphocytes than controls (P < 0.05).
• Huntington's disease patients also exhibited significantly more atypical lymphocytes than controls (P < 0.02).
• No significant difference in atypical lymphocytes was observed between schizophrenia patients on and off medication.

Conclusions:

• Elevated atypical lymphocytes are associated with schizophrenia and Huntington's disease, suggesting a potential biological link beyond medication effects.
• The findings challenge the notion that atypical lymphocytes are solely an effect of antipsychotic drugs in schizophrenia.
• Further research on first-admission, never-medicated patients is recommended to confirm these findings.